|
Status |
Public on Dec 06, 2007 |
Title |
MPR006836 |
Sample type |
RNA |
|
|
Source name |
tumor sample
|
Organism |
Homo sapiens |
Characteristics |
studyCode = 39 treatment = Dex sex = Male race = White Age_at_Randomization = 50 Date_of_Randomization = 21-Nov-02 Myeloma_Measure = IGG PGx_Response = PD PGx_Responder = NR PGx_Progression(0=No,1=Yes) = 1 PGx_Days_To_Progression = 64 Days_Survived_From_Randomization = 903 albumin = 34 C_Reactive_Protein = 4 Beta2_Microglobulin = 2.1 Number_of_Prior_Lines = 4 meanMyelScore = 9.73 Mayo_Clinic_ProliferativeIndex = 1.629184329 TC_Class_2006 = D1
|
Treatment protocol |
samples were subject to a rapid enrichment procedure (see details in http://bloodjournal.hematologylibrary.org/cgi/content/full/109/8/3177) and tumor cell pellet was frozen
|
Growth protocol |
tumor samples were collected during patient screening period prior to entry into clinical trials for the treatment of multiple myeloma
|
Extracted molecule |
total RNA |
Extraction protocol |
Total RNA was isolated using Qiagen RNAeasy kit
|
Label |
biotin
|
Label protocol |
A standard T7 based amplification protocol (Affymetrix) was used to convert 2.0 microgram of RNA to biotinylated cRNA.
|
|
|
Hybridization protocol |
cRNA for each sample was hybridized in triplicate to the U133A/B array. Data represent median of replicates that passed array QC.
|
Scan protocol |
Microarrays were scanned with GeneArray 3000 scaner (Affymetrix).
|
Description |
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib
|
Data processing |
Dataprocessing used Affymetrix MAS5.0.
|
|
|
Submission date |
Dec 04, 2007 |
Last update date |
Dec 05, 2007 |
Contact name |
George Mulligan |
Organization name |
Millennium Pharmaceuticals
|
Department |
Clinical Development
|
Street address |
35 Landsdowne Stree
|
City |
Cambridge |
State/province |
MA |
ZIP/Postal code |
02139 |
Country |
USA |
|
|
Platform ID |
GPL97 |
Series (1) |
GSE9782 |
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib |
|